| Name | Title | Contact Details |
|---|
NeuBase is developing ultra precision genetic medicines targeting rare, monogenic diseases, therapeutic candidates for the treatment of myotonic dystrophy type 1 (DM1), Huntington`s disease (HD), and cancer-driving point mutations in KRAS G12V and G12D, which are involved in many tumor types and have historically been “undruggable.” for which there are no approved therapies, as well as more common genetic disorders, including cancers that are resistant to current therapeutic approaches. NeuBase`s pipeline includes
Johnson Matthey Pharmaceutical - West Deptford is a Paulsboro, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Molecular NeuroImaging is a New Haven, CT-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Sage Recovery & Wellness Center Austin is an outpatient center specializing in both mental health and substance use, utilizing a holistic approach to recovery.
PCI is a leading provider of integrated pharmaceutical development services to the global healthcare market.